September 2, 2021 |

Events & Presentations

2021 ISGEDR Meeting (International Society for Genetic Eye Diseases & Retinoblastoma)

GenSight Biologics is a Gold sponsor of the 2021 ISGEDR Meeting (International Society for Genetic Eye Diseases & Retinoblastoma). Senior management will attend and be present as well as oral presentations on LUMEVOQ^® and GS030 will be featured at the 2021 ISGEDR meeting in Lausanne (Switzerland) in September 2-4, 2021. “The Phase III REFLECT Trial: Efficacy and Safety of Bilateral Gene Therapy for Leber Hereditary Optic Neuropathy (LHON)” will be presented by Bart Leroy, MD, Ghent University Hospital, Belgium (Investigator in the REFLECT trial).

• Oral Presentation
• Session 1 – Ophthalmic Genetics 3: Treatment of Inherited Retinal Disorders
• Abstract Number: OcGen31
• Thursday, September 2, 2021, 12:12 – 12:22 pm CEST

“Optogenetics: The Generic Future?” will be presented by José-Alain Sahel, MD, University of Pittsburgh School of Medicine, United States (Co-founder of GenSight Biologics).

• Oral Presentation
• Session 2 – Symposium: Gene Therapy (Nuclear Genes)
• Abstract Number: OcGenInvited5
• Thursday, September 2, 2021, 2:30 – 2:40 pm CEST

 “New Insights into Leber Hereditary Optic Neuropathy” will be presented by Patrick Yu-Wai-Man, MD, University of Cambridge, United Kingdom (Investigator in the RESCUE, REVERSE and REFLECT trials).

• Oral Presentation
• Session 6 – Symposium: Mitochondrial Genetics & Optic Neuropathies
• Abstract Number: OcGenInvited10
• Saturday, September 4, 2021, 2:20 – 2:35 pm CEST

 “Gene Therapy for Leber Hereditary Optic Neuropathy” will be presented by Catherine Vignal, MD, Fondation Rothschild Hospital, Paris, France (Investigator in the RESCUE, REVERSE and REFLECT trials).

• Oral Presentation
• Session 6 – Symposium: Mitochondrial Genetics & Optic Neuropathies
• Abstract Number: OcGenInvited11
• Saturday, September 4, 2021, 2:35 – 2:50 pm CEST